Medpace (MEDP) – Analysts’ Weekly Ratings Changes

Medpace (NASDAQ: MEDP) has recently received a number of price target changes and ratings updates:

• 10/26/2026 – Medpace had its price target raised by BMO Capital Markets from $600.00 to $670.00. They now have a “market perform” rating on the stock.
• 10/23/2026 – Medpace had its price target raised by Truist Financial from $609.00 to $633.00. They now have a “hold” rating on the stock.
• 10/23/2026 – Medpace had its price target raised by UBS Group from $673.00 to $700.00. They now have a “neutral” rating on the stock.
• 10/23/2026 – Medpace was given a new $730.00 price target by Mizuho.
• 10/23/2026 – Medpace was given a new $699.00 price target by Robert W. Baird.
• 10/23/2026 – Medpace had its price target raised by Barclays from $625.00 to $675.00. They now have an “equal weight” rating on the stock.
• 10/23/2026 – Medpace had its price target raised by TD Cowen from $492.00 to $673.00. They now have a “hold” rating on the stock.
• 10/8/2026 – Medpace was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/7/2026 – Medpace had its price target raised by Mizuho from $665.00 to $700.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Medpace had its price target raised by Barclays from $600.00 to $625.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Medpace is now covered by UBS Group. They set a “neutral” rating and a $673.00 price target on the stock.
• 9/30/2026 – Medpace was upgraded by UBS Group from “sell” to “hold”. They now have a $673.00 price target on the stock, up from $405.00.
• 9/14/2026 – Medpace had its “hold” rating reaffirmed by Jefferies Financial Group.

Medpace Trading Up 0.4%

NASDAQ MEDP traded up $2.38 on Wednesday, reaching $666.92. The company’s stock had a trading volume of 43,986 shares, compared to its average volume of 326,266. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $693.97. The firm has a market cap of $18.66 billion, a PE ratio of 36.97, a price-to-earnings-growth ratio of 2.61 and a beta of 1.12. The business has a 50-day moving average price of $625.40 and a 200 day moving average price of $532.88.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating the consensus estimate of $4.44 by $0.40. The company had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.86 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 18.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 49,018 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total value of $30,788,695.98. Following the completion of the sale, the chief executive officer directly owned 433,372 shares in the company, valued at approximately $272,205,286.92. This trade represents a 10.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 16,060 shares of Medpace stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $677.00, for a total value of $10,872,620.00. Following the completion of the transaction, the vice president directly owned 57,624 shares of the company’s stock, valued at $39,011,448. This represents a 21.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 306,997 shares of company stock valued at $192,049,408. Corporate insiders own 20.50% of the company’s stock.

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.